Mode
Text Size
Log in / Sign up

Meta-analysis finds fatty pancreas disease in over half of adults with MASLDDo you have fatty liver? A new look suggests your pancreas might be fatty too

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Recognize fatty pancreas disease is common in MASLD but its clinical relevance is uncertain.

This systematic review and meta-analysis pooled data from 11 observational studies involving 21,438 adults diagnosed with metabolic dysfunction-associated steatotic liver disease (MASLD). The analysis examined the prevalence and clinical characteristics of fatty pancreas disease (FPD) in this population, comparing those with FPD to those without FPD.

The pooled prevalence of FPD among patients with MASLD was 54.32% (95% CI 34.53 to 72.83). Significant regional variation was observed, with a prevalence of 35.59% in Asian studies and 75.05% in non-Asian studies (p=0.01). Patients with MASLD and concurrent FPD were characterized as older, having a higher body mass index, and having a greater likelihood of diabetes, hypertension, and metabolic syndrome compared to MASLD patients without FPD. Safety and tolerability data were not reported.

A key limitation is the exceptionally high statistical heterogeneity among the included studies (I²=99.6%), which significantly reduces confidence in the pooled estimate. The evidence is purely observational, establishing association only, not causation. The prognostic or therapeutic relevance of FPD in MASLD management is not established. For practice, clinicians should recognize that FPD is a common concurrent finding in MASLD, particularly in patients with more advanced metabolic comorbidities, but the clinical implications of this association remain unclear.

Imagine checking your liver for fat and finding it there. Now, think about what that might mean for your pancreas. A massive review of medical records examined over 21,000 adults who already had fatty liver disease. The goal was simple: see how often their pancreas was also filled with fat and what other health issues they had.

The results showed that about 54% of these patients had fatty pancreas disease. This number varied greatly depending on where the study took place. In Asian populations, the rate was lower at roughly 35%, while in non-Asian groups, it jumped to over 75%. Patients with both conditions tended to be older, had higher body mass index, and were more likely to have diabetes, high blood pressure, and metabolic syndrome.

But there is a major catch. The data comes from observational studies, which only show an association, not a cause. Think of it like seeing two friends always walking together; it does not mean one made the other walk. Furthermore, the studies were so different from each other that the overall picture was very unclear. We simply do not know if having a fatty pancreas makes the liver disease worse or if they just happen together.

What this means for you:
About half of adults with fatty liver also have a fatty pancreas, but this link is based on association, not proof of cause.

Study Details

Study typeMeta analysis
Sample sizen = 438
EvidenceLevel 1
PublishedApr 2026
View Original Abstract ↓
BACKGROUND AND AIMS: Fatty pancreas disease (FPD), characterized by excessive intrapancreatic fat deposition (IPFD), is increasingly recognized as a manifestation of metabolic dysfunction. However, its epidemiology and clinical impact in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) remain unclear. We conducted a systematic review and meta-analysis to quantify the prevalence of FPD in MASLD and to compare clinical characteristics between patients with and without FPD. METHODS: A comprehensive search of the PubMed and Embase databases was conducted from inception to November 29, 2025, to identify observational studies reporting the prevalence and/or clinical impact of FPD in adults with MASLD. Pooled prevalence estimates were calculated using a generalized linear mixed model, and clinical features were compared using random-effects models. RESULTS: We identified 11 studies (n = 21 438 patients). The pooled prevalence of FPD in MASLD was 54.32% (95% CI 34.53 to 72.83), with high heterogeneity (I = 99.6%). FPD prevalence was significantly lower in Asian studies (35.59%) than in non-Asian studies (75.05%) (p = 0.01). No differences in FPD prevalence were found when stratified by sample size, MASLD diagnosis, or IPFD assessment method. Patients with MASLD and FPD were found to be older, had a higher body mass index, and were more likely to have diabetes, hypertension, and metabolic syndrome. CONCLUSIONS: Around half of patients with MASLD have concomitant FPD, which is associated with an adverse cardiometabolic phenotype. These findings support the need for integrated, longitudinal evidence to define the prognostic and therapeutic relevance of IPFD within a multiorgan ectopic fat framework of systemic metabolic dysfunction.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.